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shows synovial fluid CS content of the 3 groups as determined
by DMMB. For comparison, Figure 1B shows total sulfated chon-
droitin disaccharide (delta di6S and delta di4S) for the same
samples determined by FACE. For both methods, CS peak oc-
curs at fraction 18 in synovial fluid from joints with OC injury.
Similarly, CS in synovial fluid from exercised joints peaks in frac-
tion 19 with both assays. CS in synovial fluid from rested joints
peaks in fraction 19 when determined by DMMB, but peaks in
fraction 20 when measured by FACE. When ug/ml amounts of
CS for each data point were compared between assays, results
for exercised (n=80) and OC injury joints (n=70) were signifi-
cantly different (P<0.0001), but results for rested joints (n=80)
were not (P=0.92).
Conclusions: When used for quantitation of sulfated CS in syn-
ovial fluid (ug/ml), DMMB gave results that were significantly
different than those from FACE. DMMB may be measuring other
sGAGs in addition to CS. However, when performed after Su-
perose 6 chromatography, DMMB assay appears to discriminate
the longer CS chains in synovial fluid from OC injured joints from
the shorter chains seen in normal joints. Thus, for the specific
purposes of determination of CS chain length, the more simple,
less expensive DMMB assay may be a replacement for FACE
assay. Use of a 384-well microplate allowed use of low volumes
of DMMB reagents. This facilitated quantitation of small amounts
of CS in fractions collected from Superose 6 chromatography.
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Purpose: Adipocytokines resistin and adiponectin are the major
members of adipose tissue-derived peptides, which have been
suggested as a link between insulin resistance, diabetes, and
obesity. Recent data provided also body of evidence on the
implication of adipocytokines in the inflammation, immune re-
sponse, and tissue destruction. This study was undertaken to
examine the (patho)physiological role of resistin and adiponectin
in matched serum and synovial fluid samples from patients with
rheumatoid arthritis (RA) and osteoarthritis (OA).
Methods: Blood and synovial fluid samples from 20 RA and 20
OA patients were analyzed for resistin and adiponectin (ELISA,
Biovendor). The clinical activity of patients with OA and RA
was assessed according to the Western Ontario and McMaster
Universities (WOMAC) index and the 28 joint count Disease
Activity Score (DAS28), respectively.
Results: Serum resistin levels were significantly lower in OA
compared to RA patients (p=0.002), however the levels of
adiponectin in those patients were comparable (p=0.38).
The levels of both adipocytokines in synovial fluid were signifi-
cantly lower in OA than in RA patients (p<0.001). Adiponectin
concentration was lower in synovial fuid than that in systemic
circulation in both diseases. However, in contrast to OA patients,
resistin levels were significantly higher in synovial fluid than in
systemic circulation in RA patients. In RA patients, increased
serum resistin correlated positively with CRP (r=0.53, p<0.02)
and DAS28 (r=0.44, p<0.05), and adiponectin correlated nega-
tively with leukocyte count in synovial fluid (r= -0.45, p<0.05).
No such correlation was observed in OA patients.
Conclusions: The local up-regulation of adipocytokines in RA
synovial fluid points to a possible role of these molecules in
the pathophysiology of inflammatory joint diseases such as RA
rather than OA.
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Purpose: Aggrecan is the major proteoglycan in articular carti-
lage, and is degraded and released from the extracellular matrix
in pathological joint debilitating diseases like osteoarthritis (OA).
The aggrecanases, ADAMTS-4 and ADAMTS-5, and an array
of Matrix Metallo Proteinases (MMPs) are up-regulated in os-
teoarthritis (OA). The aim of the current study was to monitor the
aggrecanase and MMP mediated turnover of aggrecan in human
OA cartilage in response to different cytokines.
Methods: Articular cartilage was obtained from OA patients,
who had undergone total knee arthroplasty. Articular cartilage
was cultured for 21 days with refreshment of medium every 3rd
day in the presence of 100 ng/mL Interleukin-1 alpha (IL-1α)
or 10 ng/ml Oncostatin M (OSM) + 20 ng/mL Tumour Necro-
sis Factor alpha (OSM/TNFα) to stimulate cartilage degradation.
As negative control, explants without cytokine stimulation were
